RXi

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced that it has started a third Phase IIa trial for its anti-scarring treatment RXI-109.

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

RXi Pharmaceuticals has appointed Peter Campochiaro to its scientific advisory board.

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported a slight increase in its first-quarter net loss on modestly higher costs.

NEW YORK (GenomeWeb) – RXi Pharmaceuticals last week announced positive preclinical data from a program exploring the use of its anti-scarring drug candidate RXI-109 in ophthalmic conditions, showing that intravitreal injection of the agent cut levels of its target protein in the eyes of non-huma

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced the start of a Phase IIa trial of its siRNA-based anti-scarring drug RXI-109 for the prevention of keloid recurrence.

NEW YORK (GenomeWeb) – Amid a recent downturn among biotechnology stocks, shares of the top eight publicly traded RNAi and microRNA drug developers have fared particularly poorly, shedding an average of 37 percent of their value from their year-to-date highs.

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced that it has signed a deal under which investment firm Lincoln Park Capital Fund has agreed to buy up to $20 million worth of RXi shares over the next 30 months.